Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stem Cells SpinWAR:SCS -0.41%25 Equity-to-Asset is 0.68 as of Mar. 2026, which is 28% above its 10-year median of 0.53. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Stem Cells Spin ranks better than 50.35% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Stem Cells Spin's Total Stockholders Equity for the quarter that ended in Mar. 2026 was zł6.21 Mil. Stem Cells Spin's Total Assets for the quarter that ended in Mar. 2026 was zł9.15 Mil.
Therefore, Stem Cells Spin's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.68.
The historical rank and industry rank for Stem Cells Spin's Equity-to-Asset or its related term are showing as below:
WAR:SCS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23 Med: 0.53 Max: 0.68
Current: 0.68
During the past 13 years, the highest Equity to Asset Ratio of Stem Cells Spin was 0.68. The lowest was 0.23. And the median was 0.53.
WAR:SCS's Equity-to-Asset is ranked better than 50.35% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs WAR:SCS: 0.68
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Stem Cells Spin Equity-to-Asset Related Terms
Stem Cells Spin Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Stem Cells Spin's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Stem Cells Spin's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a Equity-to-Asset of 0.68 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Stem Cells Spin and its competitors. This is 28% above median its historical median of 0.53. Over the past decade, Stem Cells Spin's Equity-to-Asset has ranged from 0.23 to 0.68. According to the industry distribution chart, Stem Cells Spin ranks #703 out of 1416 companies in the Biotechnology industry, placing it in the top 49.6%.
Is Stem Cells Spin's Equity-to-Asset too high?
Stem Cells Spin's current Equity-to-Asset of 0.68 is 28% above median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 0.68. The Biotechnology industry median Equity-to-Asset is 0.68. Stem Cells Spin's value of 0.68 is 0% at this industry median. Based on the distribution chart, Stem Cells Spin ranks #703 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #703 out of 1416 companies for Equity-to-Asset. This puts Stem Cells Spin in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Stem Cells Spin's value of 0.68 is 0% at this benchmark. Historically, Stem Cells Spin's own Equity-to-Asset has ranged from 0.23 to 0.68 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 0.68, Stem Cells Spin has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current Equity-to-Asset of 0.68 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current Equity-to-Asset is 0.68, which is 28% above median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.48 — trading 384% above its estimated fair value. The current Equity-to-Asset is 0.68, which is 28% above median its 10-year median of 0.53 and 0% at the Biotechnology industry median of 0.68. Stem Cells Spin's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Equity-to-Asset is 0.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.48 is trading 384% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
Equity-to-Asset: 0.68 (28% above median its 10-year median of 0.53)
GF Value™: zł0.10 vs. price of zł0.48 (384% above fair value)
Industry Position: 0% at the Biotechnology median (#703 of 1416)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
